Suzuken : Notice Regarding Completion of Cancellation of Treasury Stock
March 29, 2024 at 02:02 am EDT
Share
March 29, 2024
Press Release
SUZUKEN CO., LTD.
Shigeru Asano, President and CEO (Stock Code: 9987)
Securities Traded: Prime Markets of the Tokyo and Nagoya Stock Exchanges, and the Sapporo Securities Exchange Contact: Yuichi Yamamoto, Executive Officer, Senior General Manager of Corporate Group Planning Headquarters Tel.: +81-52-961-2331
Notice Regarding Completion of Cancellation of Treasury Stock
Suzuken Co., Ltd. hereby announces that, as resolved at the meeting of its Board of Directors held on November 10, 2023, a cancellation of treasury shares was completed on March 29, 2024, pursuant to Article 178 of the Companies Act of Japan.
1.
Type of shares canceled
Common shares
2.
Number of shares canceled
5,091,032 shares
(6.1% of the number of outstanding shares before cancellation)
3.
Date of cancellation
March 29, 2024
[Reference]
Number of outstanding shares after cancellation
77,740,872 shares
*For more details regarding the resolution dated November 10, 2023, please refer to
"Notice Regarding Resolution to Acquire Treasury Shares and Cancellation of Treasury Shares".
This is an English translation of a statement written initially in Japanese and is provided for reference purposes only.
The Japanese original shall prevail in the event of any discrepancy between this document and the original.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Suzuken Co. Ltd. published this content on
29 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
29 March 2024 06:01:04 UTC.
Suzuken Co Ltd is a Japan-based company mainly engaged in the manufacture and sale of pharmaceutical products. The Company operates in four business segments. The Pharmaceutical Wholesale segment sells pharmaceuticals, diagnostic drugs, and medical equipment and materials, among others. The Pharmaceutical Manufacturing segment manufactures pharmaceuticals and diagnostic drugs and others. The Insurance Pharmacy segment is engaged in dispensing operations based on prescriptions from medical institutions. The Medical-related Service and Others segment is engaged in the provision of manufacturer support services, such as the transportation of medicines and comprehensive support for the distribution of drugs for rare diseases; the nursing services; the manufacture of physiological examination equipment, such as electrocardiographic monitors and blood pressure monitors; as well as other services, such as the sale of medical books.
SUZUKEN CO., LTD. 
